Chai Phua: 1st Publicly Funded Hemgenix Treatment for Hemophilia B in Canada Marks Historic Gene Therapy Milestone
Chai Phua, Associate Professor at Schulich School of Medicine and Dentistry, shared on LinkedIn:
”A historic milestone for bleeding disorders care in Canada.
Last week, the first publicly funded Canadian patient received Hemgenix for Hemophilia B at London Health Sciences Centre.
While this moment represents a major step forward in gene therapy and hemophilia B care, it also reflects decades of foundational work by leaders, clinicians, researchers, nurses, hemostasis laboratories, blood banks, patient advocates, and the broader bleeding disorders community across Canada who helped build the systems, expertise, and advocacy needed to make innovative therapies like this possible.
Most importantly, this milestone represents hope not only for one patient, but for the future of innovative therapies in rare diseases across Canada.
Thank you to everyone who helped make this possible.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 02:38Brianne D.: Sex Differences in RIPK1 Signaling Following Intracerebral Hemorrhage
-
Oct 10, 2026, 02:17Dino Mehic: Managing Heavy Menstrual Bleeding in Patients with BDUC
-
Oct 10, 2026, 00:34Raphaëlle Dodart: Discussing the Mechanisms of Menstrual Hemostasis
-
Oct 10, 2026, 00:26Barbara Adams Krolak: Discussing the Growing Need for Blood Clot Prevention in Asia
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia